NGL Fine Chem Ltd
NGL Fine Chem Ltd Q1 FY25 Results & Presentation Highlights: Revenue ₹90.75 Cr, PAT ₹9.22 Cr
Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on NGL Fine Chem Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Q1FY25 EBITDA: ₹9.35 crores; Year-on-Year (YoY) change: -5.20% - Q1FY25 EBITDA Margin: 10.30%; YoY change: -358 basis points - Q1FY25 Profit After Tax (PAT): ₹9.22 crores; YoY change: +8.37% - O
From NGL Fine Chem Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8).
- Total income in Q1 FY25: ₹96.64 crores, a 29.95% YoY increase.
- Sales volume growth indicated through revenue, reflecting robust demand (Management Commentary, Page 6).
- Q-o-Q revenue declined 9.03% due to increased competition and traditional slower period post-Q4 FY24’s high sales (Page 8, 6).
- No specific volume figures provided, only revenue and sales growth percentages.
- Outlook: Pricing pressure expected to persist into Q2 FY25 but conditions are anticipated to improve as the year progresses (Page 6).
2 more points management made on revenue & sales performance
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield expansion at Tarapur:
- Estimated capex: ₹160 crore
- Funding: Debt and internal accrual
- Status: Civil construction ongoing; ₹52.57 crore invested till Q1FY25
- Purpose: 50% capacity expansion to meet demand for new products in pipeline
- Brownfield expansion:
- Completed in subsidiary Macrotech
- Added capacities of intermediates
- Commercial production started
- Capex plans:
- Phase 1 expected completion by Q4 FY25
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Shree Ganesh Remedies Ltd (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY
- Themis Medicare Ltd (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q1 FY25 investor presentation — and how it ranks against sector
- Fermenta Biotech Ltd (Q1 FY25)
The Annual Standalone Financial Performance (Page 26) reports full-year FY24 operational revenue of INR 3,071 million, down 6.6% YoY from INR 3,289 million in…
- Fermenta Biotech Ltd (Q1 FY25)
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key investor presentation takeaways from Fermenta Biotech L
Frequently Asked Questions
What were NGL Fine Chem Ltd Q1 FY25 results?
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Q1FY25 EBITDA: ₹9.35 crores; Year-on-Year (YoY) change: -5.20% - Q1FY25 EBITDA Margin: 10.30%; YoY change: -358 basis points - Q1FY25 Profit After Tax (PAT): ₹9.22 crores; YoY change: +8.37% - O
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield expansion at Tarapur: - Estimated capex: ₹160 crore - Funding: Debt and internal accrual - Status: Civil construction ongoing; ₹52.57 crore invested till Q1FY25 - Purpose: 50% capac
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.